跳至主要内容
临床试验/CTRI/2024/11/076722
CTRI/2024/11/076722尚未招募3 期

Effect of Vacha churna as compared to Sarpagandha churna in the management of stage-1 essential Hypertension:A randomised controlled trial

Vd Rekha Gajanan Mehenge1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年11月20日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
60
试验地点
1
主要终点
Vacha churna is more effective than Sarpagandha churna in the management of stage-1 essential hypertension

研究概览

简要总结

In the present study total 60 participants will be taken for trial dividing them in equal groups.Group A will receive the trial drug "Vacha churna" & Group B will receive the control drug "Sarpagandha churna" twice a day for internally for 30 days.Follow up will be taken every 8 days.result will be concluded based on assessment criteria.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
30.00 Year(s) 至 50.00 Year(s)(—)
性别
All

入选标准

  • Newly diagnosed patients of stage -1 essential hypertension.

排除标准

  • Secondary hypertension.

结局指标

主要结局

Vacha churna is more effective than Sarpagandha churna in the management of stage-1 essential hypertension

时间窗: at the end of 30 days

次要结局

  • Sarpagandha churna is more effective than Vacha churna in the management of stage-1 essential hypertension(At the end of 30 days)

研究者

发起方
Vd Rekha Gajanan Mehenge
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Vd Rekha Gajanan Mehenge

Shri ayurved mahavidyalaya nagpur

研究点 (1)

Loading locations...

相似试验